Optellum, Ai Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding To Accelerate Expansion

Company

Location

About

Optellum was founded so that every lung cancer patient is treated at the earliest possible stage, and cured. We are redefining early interception of lung disease, by enabling every clinician, in every hospital, to manage their patients in the optimal way. Our first product is the first Clinical Decision Support software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning applied to the world’s largest clinical dataset. We are a team of world-leading medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision laboratory. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians (global authors of medical guidelines) and experts in deep learning. We are building up our development team – join our fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups.